Century Therapeutics Inc.
IPSC | NASDAQ
$1.88
+$0.03 (+1.62%)
Sep 22, 2026, 12:37 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 109.16M | 6.59M | 2.24M | 5.2M | n/a | n/a |
Cost of Revenue | 13.1M | n/a | n/a | n/a | 4.58M | 1.75M |
Gross Profit | 96.06M | 6.59M | 2.24M | 5.2M | -4.58M | -1.75M |
Operating Income | -15.04M | -138.14M | -146.55M | -133.83M | -94.88M | -49.18M |
Interest Income | 7.35M | 13.01M | 12.68M | 2.99M | 898K | 704K |
Pretax Income | -9.65M | -124.78M | -134.79M | -130.84M | -95.78M | -53.58M |
Net Income | -9.58M | -126.57M | -136.67M | -130.93M | -95.82M | -53.58M |
Selling & General & Admin | 24M | 33.16M | 34.71M | 31.86M | 14.65M | 7.74M |
Research & Development | 95.67M | 107.24M | 92.71M | 97.17M | 75.65M | 39.68M |
Other Expenses | -8.57M | 4.33M | 21.37M | 10M | n/a | n/a |
Operating Expenses | 111.1M | 144.73M | 148.78M | 139.03M | 90.3M | 47.42M |
Interest Expense | n/a | n/a | 540K | n/a | 1.28M | 381K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 124.2M | 144.73M | 148.78M | 139.03M | 94.88M | 49.18M |
Income Tax Expense | -68K | 1.79M | 1.88M | 91K | 43K | n/a |
Shares Outstanding (Basic) | 86.56M | 78.65M | 59.31M | 57.76M | 55.01M | 54.82M |
Shares Outstanding (Diluted) | 86.56M | 78.65M | 59.31M | 57.76M | 55.01M | 54.82M |
EPS (Basic) | -0.11 | -1.61 | -2.30 | -2.27 | -1.74 | -1 |
EPS (Diluted) | -0.11 | -1.61 | -2.30 | -2.27 | -1.74 | -1 |
EBITDA | 3.45M | -111.47M | -121.21M | -121.2M | -89.92M | -51.44M |
EBIT | -9.65M | -124.78M | -134.25M | -129.64M | -94.51M | -53.19M |
Depreciation & Amortization | 13.1M | 13.3M | 13.04M | 8.44M | 4.58M | 1.75M |
Add to Watchlist
Select watchlists to add or remove IPSC